What is the recommended antibiotic treatment for a 46-year-old patient with pneumonia?

Antibiotic Treatment for Pneumonia in a 46-Year-Old

Community-Acquired Pneumonia (Outpatient or Non-Severe Hospitalized)

For a 46-year-old with community-acquired pneumonia requiring hospitalization for clinical reasons, the preferred treatment is combination therapy with oral amoxicillin PLUS a macrolide (erythromycin or clarithromycin). 1, 2

First-Line Regimen

• Amoxicillin PLUS macrolide (erythromycin or clarithromycin) is the preferred combination for hospitalized patients with non-severe CAP 1, 2
• Most patients can be adequately treated with oral antibiotics unless contraindications exist 1, 2
• This combination provides coverage for both typical bacteria (particularly Streptococcus pneumoniae) and atypical pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella) which account for up to 40% of CAP cases 3

Alternative Monotherapy Option

• Levofloxacin 750 mg orally once daily is an appropriate alternative, particularly for patients intolerant of penicillins or macrolides 1, 2, 4
• Levofloxacin 750 mg daily for 5 days has demonstrated equivalent efficacy to 500 mg daily for 10 days in treating CAP, including atypical pathogens 4, 5
• This agent provides enhanced activity against S. pneumoniae, including penicillin-resistant strains, with resistance prevalence <1% in the US 6

Common pitfall: Avoid using ciprofloxacin for pneumonia, as it lacks adequate pneumococcal coverage and has been associated with treatment failures 1

---

Severe Community-Acquired Pneumonia (ICU-Level Care)

For severe pneumonia requiring intensive care, immediate parenteral antibiotics are mandatory with intravenous co-amoxiclav OR cefuroxime OR cefotaxime/ceftriaxone PLUS intravenous macrolide (clarithromycin or erythromycin). 1, 2

Parenteral Regimen for Severe CAP

• IV β-lactam (co-amoxiclav, cefuroxime, cefotaxime, or ceftriaxone) PLUS IV macrolide is the preferred combination 1, 2
• Alternative: Levofloxacin 750 mg IV once daily PLUS IV benzylpenicillin for patients intolerant of β-lactams or macrolides 1, 2
• Fluoroquinolone monotherapy is NOT recommended for severe CAP in ICU patients 3, 7

Treatment Duration

• 10 days for microbiologically undefined severe pneumonia 1, 2
• 14-21 days if Legionella, Staphylococcus aureus, or Gram-negative enteric bacilli are suspected or confirmed 1, 2

Switching to Oral Therapy

• Switch from IV to oral once clinical improvement occurs, temperature has been normal for 24 hours, and no contraindication to oral route exists 2

---

Hospital-Acquired Pneumonia (If Applicable)

If this is hospital-acquired pneumonia (onset ≥48 hours after admission), treatment depends on MRSA risk factors and mortality risk. 1, 2

Low-Risk HAP (No MRSA Risk Factors)

• Piperacillin-tazobactam 4.5 g IV q6h OR cefepime 2 g IV q8h OR levofloxacin 750 mg IV daily 1, 2

High-Risk HAP or MRSA Risk Factors

MRSA coverage is required if: 1, 2

• Prior IV antibiotic use within 90 days
• Unit MRSA prevalence >20% or unknown
• High mortality risk (ventilatory support, septic shock)

Add MRSA coverage: 1, 2

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL) OR
• Linezolid 600 mg IV q12h

Plus one of the following for Gram-negative coverage: 1

• Piperacillin-tazobactam 4.5 g IV q6h
• Cefepime 2 g IV q8h
• Levofloxacin 750 mg IV daily
• Meropenem 1 g IV q8h

Critical consideration: For patients with structural lung disease (bronchiectasis, cystic fibrosis) or high risk of Gram-negative infection, use TWO antipseudomonal agents to prevent resistance emergence 1, 7